MedTrace Logo

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

NCT00817375 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2015-12-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4\~6 weeks after drug administration.

Conditions

Interventions

DRUG

SSRI treated group

Antidepressant administration of SSRI class for 6 weeks under therapeutic dose

DRUG

non-SSRI treated group

Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Doh Kwan Kim, M.D., Ph.D. · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00817375 on ClinicalTrials.gov